Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Zelnorm uptake

Executive Summary

More than 70% of "top-tier" gastrointestinal specialists are prescribing the irritable bowel syndrome agent Zelnorm, Novartis Pharmaceutical CEO Thomas Ebeling tells investors April 15. "Tier one" physicians have on average 16-18 patients on tegaserod, he says. By comparison, second and third tier specialists have six to eight patients on the IBS agent, with roughly 45% and 35% of tier two and three physicians prescribing, respectively. Novartis previously described uptake for the specialist community as a whole, with 25% prescribing Zelnorm (1"The Pink Sheet" Oct. 21, 2002, p. 24)...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

PS041705

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel